Physician profile
Guy W Robins
NPI 1295799120
$2,769.07
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,163 · 2020: $480 · 2021: $476 · 2022: $239 · 2023: $299 · 2024: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $410.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $459.73 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $378.56 | 2019-2022 | |
| Pfizer INC. | $306.03 | 2019-2023 | |
| Abbvie INC. | $268.39 | 2020-2024 | Vraylar |
| Novo Nordisk INC | $205.36 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $191.48 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $132.50 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $132.15 | 2019-2021 | |
| Allergan, INC. | $87.66 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $80.42 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.14 | 2019-2024 | Synjardy, Jardiance |
| Lilly USA, LLC | $67.44 | 2019-2023 | Mounjaro |
| Kowa Pharmaceuticals America, INC. | $55.64 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $52.63 | 2019-2020 | |
| Esperion Therapeutics, INC. | $50.43 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.27 | 2019-2022 | |
| Bausch Health US, LLC | $28.89 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $26.31 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $25.17 | 2020 | |
| Nevro Corp. | $20.80 | 2023 | Senza |
| Assertio Therapeutics, INC. | $16.93 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.64 | 2021 | |
| Amarin Pharma, INC. | $13.63 | 2020 | |
| Astellas Pharma US INC | $12.80 | 2023 | Veozah |
| Shire North American Group INC | $12.16 | 2019 | |
| Circassia INC. | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guy Robins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.